Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TLE3 CRISPR/Cas9 KO Plasmid (h): sc-400386
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TLE3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TLE3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TLE3 Antibody (D-10): sc-514798
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TLE3 CRISPR/Cas9 KO Plasmid (h) | sc-400386 | 20 µg | $397.00 |
Overview
TLE3 (transducin-like enhancer of split 3) encodes a Groucho/TLE family transcriptional corepressor that binds DNA-associated factors such as TCF/LEF, HES/HEY, and other lineage regulators to modulate gene expression programs during development and tissue homeostasis. By recruiting chromatin-modifying complexes, TLE3 influences Wnt/β-catenin-dependent transcription, Notch effector outputs, and additional differentiation-linked pathways. Altered TLE3 activity has been linked to dysregulated cell fate decisions, proliferation control, and transcriptional reprogramming observed across multiple disease contexts, including cancer biology and metabolic phenotypes. These properties make TLE3 a useful target for dissecting pathway crosstalk and epigenetic control of context-specific transcription.
TLE3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TLE3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TLE3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TLE3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TLE3 protein expression.
This CRISPR knockout system enables efficient generation of TLE3-deficient cell models for investigation of TLE3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TLE3 exon(s) critical for TLE3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TLE3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TLE3 CRISPR/Cas9 KO Plasmid (h) and TLE3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TLE3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TLE3 HDR Plasmid (h) and TLE3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TLE3 homology arms to support homology-directed repair at defined TLE3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.